Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeynep Eroglu

Showing results (31-40 of 116) with videos related to

Pageof 12
Sort By:
Journal for Immunotherapy of Cancer|December 30, 2016
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanomaAndrew S Brohl, Nikhil I Khushalani, Zeynep Eroglu, et al.
Geriatrics & Gerontology International|July 10, 2026
The Relationship Between Voluntary Rapid Blinking Rate and Future Development of Neurodegenerative DiseaseRemzi Bahsi, Zeynep Eroglu Soysal, Volkan Atmis, et al.
Cancers|February 27, 2026
Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-AnalysisIslam Eljilany, Eissa Jafari, Abdullah Alhumaid, et al.
Seminars in Cancer Biology|November 6, 2019
Translational pathology, genomics and the development of systemic therapies for acral melanomaYian Ann Chen, Jamie K Teer, Zeynep Eroglu, et al.
Cancers|June 28, 2023
Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell CarcinomaJulian A Marin-Acevedo, Bethany M Withycombe, Youngchul Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2ADiwakar Davar, Zeynep Eroglu, Casilda Llácer Pérez, et al.
Pigment Cell & Melanoma Research|April 19, 2016
Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrumDouglas B Johnson, Jason Roszik, Alexander N Shoushtari, et al.
Dermatology and Therapy|December 19, 2025
Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During TreatmentMark G Lebwohl, Darrell S Rigel, Zeynep Eroglu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 19, 2019
Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic MelanomaElizabeth J Davis, Matthew C Perez, Noura Ayoubi, et al.
Journal for Immunotherapy of Cancer|October 26, 2016
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunctionBridgette A Kanz, Megan H Pollack, Romany Johnpulle, et al.
Pageof 12

Showing results (31-40 of 116) with videos related to

Sort By:
Pageof 12
Journal for Immunotherapy of Cancer|December 30, 2016
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanomaAndrew S Brohl, Nikhil I Khushalani, Zeynep Eroglu, et al.
Geriatrics & Gerontology International|July 10, 2026
The Relationship Between Voluntary Rapid Blinking Rate and Future Development of Neurodegenerative DiseaseRemzi Bahsi, Zeynep Eroglu Soysal, Volkan Atmis, et al.
Cancers|February 27, 2026
Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-AnalysisIslam Eljilany, Eissa Jafari, Abdullah Alhumaid, et al.
Seminars in Cancer Biology|November 6, 2019
Translational pathology, genomics and the development of systemic therapies for acral melanomaYian Ann Chen, Jamie K Teer, Zeynep Eroglu, et al.
Cancers|June 28, 2023
Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell CarcinomaJulian A Marin-Acevedo, Bethany M Withycombe, Youngchul Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2ADiwakar Davar, Zeynep Eroglu, Casilda Llácer Pérez, et al.
Pigment Cell & Melanoma Research|April 19, 2016
Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrumDouglas B Johnson, Jason Roszik, Alexander N Shoushtari, et al.
Dermatology and Therapy|December 19, 2025
Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During TreatmentMark G Lebwohl, Darrell S Rigel, Zeynep Eroglu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 19, 2019
Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic MelanomaElizabeth J Davis, Matthew C Perez, Noura Ayoubi, et al.
Journal for Immunotherapy of Cancer|October 26, 2016
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunctionBridgette A Kanz, Megan H Pollack, Romany Johnpulle, et al.
Pageof 12